NexImmune, Inc. (NEXI)

NexImmune Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	2.12	0	0	0	0	0
Cost of Revenue	1.01	1.02	1.5	0.87	0.62	0.44
Gross Profit	1.11	-1.02	-1.5	-0.87	-0.62	-0.44
Selling, General & Admin	11.31	9.91	15.93	15.8	10.01	5.71
Research & Development	13.79	18.26	47.15	37.46	17.84	15.17
Other Operating Expenses	0.04	690.77	-0.09	-0.06	0.09	0.09
Operating Expenses	25.1	28.17	63.08	53.26	27.85	20.89
Operating Income	-25.91	-29.19	-63.08	-53.26	-27.85	-20.89
Interest Income	0.44	698.4	0.66	0.05	0.02	0.25
Interest Expense	260.33	0	-576.69	0.91	1.68	0
Other Expense / Income	2,498	701.55	576.78	-3.21	0.35	-0.09
Pretax Income	-25.86	-32.34	-62.51	-50.9	-29.87	-20.55
Income Tax	-2,758.12	-0	-576.69	0.84	1.77	-0.25
Net Income	-25.86	-32.34	514.18	-51.75	-31.64	-20.3
Shares Outstanding (Basic)	1	1	1	1	1	1
Shares Outstanding (Diluted)	1	1	1	1	1	1
Shares Change	19.88%	9.05%	5.39%	0.31%	1.05%	-
EPS (Basic)	-24.14	-30.82	534.29	-56.67	-34.76	-22.53
EPS (Diluted)	-24.14	-30.82	534.29	-56.67	-34.76	-22.53
Free Cash Flow	-70.24	-31.48	-52.45	-48.14	-27.27	-20.66
Free Cash Flow Per Share	-56.17	-30.00	-54.50	-52.71	-29.96	-22.94
Gross Margin	52.41%	-	-	-	-	-
Operating Margin	-1221.64%	-	-	-	-	-
Profit Margin	-1219.33%	-	-	-	-	-
Free Cash Flow Margin	-3312.30%	-	-	-	-	-
EBITDA	-24.6	-28.17	-62.51	-52.39	-27.12	-20.45
EBITDA Margin	-1160.28%	-	-	-	-	-
Depreciation & Amortization	0.88	1.02	0.99	0.87	0.62	0.44
EBIT	-25.48	-29.19	-63.5	-53.26	-27.74	-20.89
EBIT Margin	-1201.59%	-	-	-	-	-

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.